Additionally, a multicenter, randomized phase II study evaluated the efficacy of ficlatuzumab, a monoclonal antibody targeting hepatocyte growth factor, when administered alone or combined with cetuximab in patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who had previously shown resistance to cetuximab. Here, HGF is linked to head and neck squamous cell carcinoma.